

Financial Results for the 3rd quarter of the year ending March 31, 2020

February 6, 2020

Summary for the 3rd quarter of the year ending March 31, 2020



QJ	YoY results	Revenue : Down ¥37.1B	Operating Profit : Down ¥17.9B					
	Results	Revenue : ¥444.4B	Operating Profit: ¥21.5B					
		Revenue : Down ¥81.8B	Operating Profit : Down ¥31.0B					
Q1-Q3	YoY Results		renue and profit decreased substantially due to lower DSLR sales wed steady increase. Restructuring is progressing as planned.					
Q1-Q3		- Precision Equipment: FPD.	Revenue and profit decreased substantially due to lower revenue in					
		 Healthcare: Revenue showed increase thanks to steady sales of retinal diagnostic imaging system. Deficit was suppressed as planned. 						
		 Industrial Metrology 8 reduced capex by customers. 	Q Others: Revenue and profit decreased due to the impact of					

Operating Profit: ¥4.0B

Note: Amounts in this presentation material are rounded down to the hundred millions of yen.

Results Revenue: ¥153.4B

03

3rd quarter of the year ending March 31, 2020: Financial Highlights



Billions of yen	FY2019/3 Q3 (A)	FY2020/3 Q3 (B)	Change (B)-(A)
Revenue	190.5	153.4	-37.1
Operating Profit % vs Revenue	21.9 _{11.5%}	4.0 2.6%	-17.9
Profit before income taxes	23.2	5.8	-17.4
% vs Revenue	12.2%	3.8%	
Profit attributable to owners of the parent	17.9	3.9	-14.0
% vs Revenue	9.4%	2.5%	
FCF	16.9	0.8	-16.1
Exchange Rate :			Impact on Revenue
US \$	¥113	¥109	-5.0
EURO	¥129	¥120	Impact on Operating Profit
			-1.6

3rd quarter of the year ending March 31, 2020: Financial Highlights by Segments



Billions of yen		FY2019/3 Q3 (A)	FY2020/3 Q3 (B)	Change (B)-(A)
Imaging Products	Revenue	90.5	70.0	-23%
Business	Operating Profit	8.6	-0.8	-¥9.4B
Precision	Revenue	64.7	51.5	-20%
Equipment Business	Operating Profit	17.4	10.4	-¥7.0B
Haribbare Business	Revenue	16.3	16.5	+1%
Healthcare Business	Operating Profit	-0.2	-0.4	-¥0.2B
Industrial	Revenue	19.0	15.5	-18%
Metrology and Others	Operating Profit	-0.2 -0.4 19.0 15.5	-¥0.9B	
Corporate P/L non-attributable to	Revenue	-	-	_
any reportable segments	Operating Profit	-6.0	-6.3	-¥0.3B
Consolidated	Revenue	190.5	153.4	-19%
Consolidated	Operating Profit	21.9	4.0	-¥17.9B

1st to 3rd quarter of the year ending March 31, 2020: Financial Highlights



Billions of yen	FY2019/ Q1-Q3 (A)	FY2020/3 Q1-Q3 (B)	Change (B)-(A)
Revenue	526.2	444.4	-81.8
Operating Profit % vs Revenue	52.5 _{10.0%}	21.5 4.8%	-31.0
Profit before income taxes % vs Revenue	57.0 _{10.8%}	25.9 5.8%	-31.1
Profit attributable to owners of the parent % vs Revenue	40.7 7.7%	20.2 4.5%	-20.5
FCF	48.1	4.7	-43.4
Exchange Rate : US \$	¥111	¥109	Impact on Revenue -11.9
EURO	¥129	¥121	Impact on Operating Profit -3.8

FCF decreased YoY due to reduced profit attributable to owners of the parent and the changes of payment terms for the domestic partner companies, etc.

1st to 3rd quarter of the year ending March 31, 2020: Financial Highlights by Segments



Billions of yen		FY2019/3 Q1-Q3 (A)	FY2020/3 Q1-Q3 (B)	Change (B)-(A)
Imaging Products Business	Revenue Operating Profit	241.4 21.8 (22.2)	189.0 1.2 (2.0)	-22% -¥20.6B
Precision Equipment Business	Revenue Operating Profit	186.3 47.2 (47.2)	166.6 35.8 (35.8)	-11% -¥11.4B
Healthcare Business	Revenue Operating Profit	45.7 -2.5 (-2.5)	46.5 -1.6 (-1.6)	+2% +¥0.9B
Industrial Metrology and Others	Revenue Operating Profit	52.7 4.8 (5.6)	42.2 3.6 (3.6)	-20% -¥1.2B
Corporate P/L non-attributable to any reportable segments	Revenue Operating Profit	- -18.8 (-18.8)	– -17.4 (-15.7)	– +¥1.4B
Consolidated	Revenue Operating Profit	526.2 52.5 (53.8)	444.4 21.5 (24.1)	-16% -¥31.0B

Corporate P/L non-attributable to any reportable segments includes the gain from unused land sales of ¥3.8B and restructuring relevant expenses of ¥1.7B.

Note: OP figures in parentheses are the operating profit excluding restructuring relevant expenses.

Corporate P/L non-attributable to any reportable segments includes elimination of intersegment transactions that amount to ¥0.3B for FY2019/3 and -¥1.8B for FY2020/3.

3rd quarter of the year ending March 31, 2020: Imaging Products Business



	FY20	19/3	FY202	20/3	Change	
Billions of yen	Q3 (A)	Q1-Q3 (B)	Q3 (C)	Q1-Q3 (D)	(C) – (A)	(D) - (B)
Revenue	90.5	241.4	70.0	189.0	-20.5	-52.4
Operating Profit % vs Revenue	8.6 9.5%	21.8 9.0%	-0.8	1.2 0.6%	-9.4	-20.6
Digital Camera- Interchangeable Lens type (units sold: 1,000)	640	1,710	580	1,380	-60	-330
Interchangeable Lens (units sold: 1,000)	1,020	2,670	950	2,260	-70	-410
Compact DSC (units sold: 1,000)	450	1,300	230	730	-220	-570

• Q3 YoY Change: Revenue and profit substantially decreased due to sales volume reduction, average unit price dropped caused by product mix change in DCIL, and higher initial development cost for new products, etc. ML enjoyed increase both in revenue and sales volume, thanks to Z 50 launched last November. Restructuring is underway as planned. The cost of ¥0.8B was posted to optimize functions of sales and production.

3rd quarter of the year ending March 31, 2020: Precision Equipment Business



	FY20	19/3	FY20	20/3	Change	
Billions of yen	Q3 (A)	Q1-Q3 (B)	Q3 (C)	Q1-Q3 (D)	(C) - (A)	(D) - (B)
Revenue	64.7	186.3	51.5	166.6	-13.2	-19.7
Operating Profit % vs Revenue	17.4 26.9%	47.2 25.3%	10.4 20.2%	35.8 21.5%	-7.0	-11.4
FPD Lithography Systems (Units)	18	54	6	24	-12	-30
Semiconductor Lithography systems New/Refurbished (Units)	4/2	12/11	5/5	19/9	+1/+3	+7/-2

• Q3 YoY Change: After the peak of customers' capex for G6/G8, FPD suffered a large reduction in sales units. Semiconductor equipment sales volume grew both in new and refurbished systems. In overall, the negative impact by FPD could not be fully offset and this Business ended with decreased revenue and profit.

3rd quarter of the year ending March 31, 2020: Healthcare Business



- 1	FY20	19/3	FY20	20/3	Change		
Billions of yen	Q3 (A)	Q1-Q3 (B)	Q3 (C)	Q1-Q3 (D)	(C) – (A)	(D) – (B)	
Revenue	16.3	45.7	16.5	46.5	+0.2	+0.8	
Operating Profit	-0.2	-2.5	-0.4	-1.6	-0.2	+0.9	
% vs Revenue	-1.2%	-5.5%	-2.4%	-3.4%			

• Q3 YoY Change: Both biological microscope and retinal diagnostic imaging system have been maintaining the revenue and profit. In three quarters, retinal diagnostic imaging system posted the record sales, contributing to improvement in overall revenue. Deficit was suppressed by focusing investment themes, etc.

3rd quarter of the year ending March 31, 2020: Industrial Metrology Business and Others



- 1	FY20	19/3	FY20	20/3	Change	
Billions of yen	Q3 (A)	Q1-Q3 (B)	Q3 (C)	Q1-Q3 (D)	(C) – (A)	(D) - (B)
Revenue	19.0	52.7	15.5	42.2	-3.5	-10.5
Operating Profit	2.1	4.8	1.2	3.6	-0.9	-1.2
% vs Revenue	11.1%	9.1%	7.7%	8.5%		

• Q3 YoY Change: Revenue was largely affected by decreased customers' capex, as in 1H, in both Industrial Metrology and Other businesses. Revenue has been staying below the planned level, but profit has been proceeding nearly as planned with reduction of expenses, etc.



1. Financial results for the 3rd quarter of the year ending March 31, 2020

2. Forecast for the year ending March 31, 2020

Forecast for the year ending March 31, 2020



Revenue

• Company total forecast: ¥620B (unchanged)

Operating profit

• Company total forecast: ¥20B (unchanged)

Profit attributable to owners of the parent

• Company total forecast: ¥17B (unchanged)

Shareholder Returns

- Annual Dividend: ¥60, Interim Dividend: ¥30 (unchanged from previous forecast and FY)
- Buy-back
 - Acquired approx. 14M shares in buy-back period from Nov. 2019 to Jan. 2020 (equivalent to approx. 3.5% of the outstanding shares excluding Treasury Stock)
 - Approx. ¥20.3B has been spent to date while the upper limit is set to ¥30.0B (68% progress)
 - Newly acquired own shares will be all canceled by the end of this fiscal year (planned).

Note: The forecast above does not reflect the future impact of Novel Coronavirus outbreak.

The number of shares acquired in this fiscal year is approx. 20.7M shares including those acquired in Q1 of FY2020/3, which amounts to approx. ¥30.3B.

Forecast for the year ending March 31, 2020: Financial Highlights



Billions of yen	FY2019/3 (A)	Previous Forecast (Nov. 7) (B)	New Forecast (Feb. 6) (C)	Change (C)-(A)	Change (C)-(B)
Revenue	708.6	620.0	620.0	-88.6	±0
Operating Profit % vs Revenue	82.6 11.7%	20.0 3.2%	20.0 3.2%	-62.6	±0
Profit before income taxes % vs Revenue	87.9 _{12.4%}	23.0 3.7%	23.0 3.7%	-64.9	±0
Profit attributable to owners of the parent % vs Revenue		17.0	17.0	-49.5	±0
EPS	¥167.86	¥43.26	¥43.26	-¥124.6	±0
Annual Dividends	¥60	¥60	¥60	±0	±0
FCF	43.5	15.0	15.0	-28.5	±0
Exchange Rate :	¥111	¥107	¥108	·	Revenue
US \$	±111	¥107	±100	-15.8	2.7
EURO	¥128	¥121	¥121		perating Profit
Notos EDS (Pagis Farning per Share) - Pr				-4.7	0.2

Note: EPS (Basic Earning per Share) = Profit attributable to owner of the parent / Average number of shares during the term
Only the new forecast is calculated by approx. 0.393B shares, an average over the number of shares at the end of FY2019/3, approx. 0.396B, and the expected number of shares at the end of FY2020/3.

Forecast for the year ending March 31, 2020: Financial Highlights by Segments




Billions of yen	_	FY2019/3 (A)	Previous Forecast (Nov.7) (B)	New Forecast (Feb.6) (C)	Change (C)-(A)	Change (C)-(B)
Tuesding Duodusta	Revenue	296.1	235.0	235.0	-20.6%	±0%
Imaging Products Business	Operating	22.0	-10.0	-10.0	-¥32.0B	±¥0B
	Profit	(22.6)	(-5.0)	(-5.0)		
Precision Equipment	Revenue	274.5	255.0	255.0	-7.1%	±0%
Business	Operating	81.7	51.0	51.0	-¥30.7B	±¥0B
	Profit	(81.7)	(51.0)	(51.0)		
	Revenue	65.4	65.0	65.0	-0.6%	±0%
Healthcare Business	Operating	-1.9	-1.0	-1.0	+¥0.9B	±¥0B
	Profit	(-1.9)	(-1.0)	(-1.0)		
Industrial Metrology	Revenue	72.5	65.0	65.0	-10.3%	±0%
and Others	Operating	6.9	4.0	4.0	-¥2.9B	±¥0B
	Profit	(7.5)	(4.0)	65.0 -0.6% -1.0 +¥0.9B (-1.0) 65.0 -10.3%		
Corporate P/L non-	Revenue	_	-	-	_	_
attributable to any reportable segments	Operating	-26.1	-24.0	-24.0	+¥2.1B	±¥0B
reportable segments	Profit	(-25.6)	(-22.3)	(-22.3)		
	Revenue	708.6	620.0	620.0	-12.5%	±0%
Consolidated	Operating	82.6	20.0	20.0	-¥62.6B	±¥0B
	Profit	(84.4)	(26.7)	(26.7)		

Note: OP figures in parentheses are the operating profit excluding restructuring relevant expenses.

Corporate P/L non-attributable to any reportable segments includes elimination of intersegment transactions that amount to ¥0.6B for FY2019/3 and -¥1.8B for FY2020/3.

Forecast for the year ending March 31, 2020: Imaging Products Business





Revenue: forecast unchanged, down ¥61.1B YoY


- Camera market continues to shrink in Q4. Sales unit forecast is unchanged from the previous forecast.
- ML camera and Z mount lens increased their sales YoY, but negative sales impact by DSLR and CDSC was substantial.

Operating Profit: forecast unchanged, down ¥32.0B YoY

- The restructuring relevant expenses of ¥5.0B have been posted. Operating loss of ¥5.0B is forecasted excluding the one time cost.
- In addition to decreased revenue and profit YoY, the investment to enhance ML lineup put a high burden.
 Although efforts are made to reduce marketing and R&D costs, etc., substantial profit reduction is expected.

Forecast for the year ending March 31, 2020: Precision Equipment Business





• Revenue: forecast unchanged, down ¥19.5B YoY


- FPD: Sales unit forecast by generation is unchanged. High-priced G10.5 sales expects to grow YoY, but G6/G8 sales reduction will push down the revenue.
- Semiconductor: Sales unit forecast is unchanged both for new and refurbished systems. More sales of new systems expect to increase the revenue YoY.

Operating Profit: forecast unchanged, down ¥30.7B YoY

- OP for FY2019/3 included approx. ¥15B temporary profit by litigation settlement. Without this temporary profit, OP declined approx. ¥15.7B YoY.
- FPD profit reduction is partially compensated by Semiconductor profit increase YoY.

Forecast for the year ending March 31, 2020: Healthcare Business





Revenue: forecast unchanged, down ¥0.4B YoY


- Both biological microscope and retinal diagnostic imaging system are performing steadily as planned, yet almost flat revenue is expected due to the negative FX impact.

Operating Profit: forecast unchanged, up ¥0.9B YoY

 Focused investment is conducted in the regenerative medicine and ophthalmological diagnosis fields which halve the negative profit, and generate profit in the next FY as planned.

Forecast for the year ending March 31, 2020: Industrial Metrology Business and Others





• Revenue: forecast unchanged, down ¥7.5B YoY

- Due to reduced customers' CAPEX mainly in Asia including China, revenue decreased YoY.
- Industrial metrology: The market shares of non-contact 3D metrology systems expect to expand steadily.

Operating Profit: forecast unchanged, down ¥2.9B YoY

- To minimize the revenue drop impact on OP, efforts are made to reduce costs and expenses.
- Investment for future growth such as Precision Components & Modules Business, etc. will continue.



Reference Data

Forecast for the year ending March 31, 2020 Financial Highlights



	FY2017/3	FY2018/3	FY2019/3			FY2	2020/3 Forec	ast
Billions of yen	Full year	Full year	1H	2H	Full year	1H	2H	Full year
Revenue	749.2	717.0	335.7	372.9	708.6	291.0	329.0	620.0
Operating Profit % vs Revenue	0.7 0.1%	56.2 7.8%	30.6 9.1%	52.0 13.9%	82.6 11.7%	17.5 6.0%	2.5 0.8%	20.0 3.2%
Profit before income taxes	3.0	56.2	33.8	54.1	87.9	20.1	2.9	23.0
% vs Revenue	0.4%	7.8%	10.1%	14.5%	12.4%	6.9%	0.9%	3.7%
Profit attributable to owners of the parent	3.9	34.7	22.8	43.7	66.5	16.3	0.7	17.0
% vs Revenue	0.5%	4.8%	6.8%	11.7%	9.4%	5.6%	0.2%	2.7%
ROE	0.7%	6.3%		11.2%			3%	
FCF	56.6	90.2		43.5			15.0	
Exchange Rate : US \$ EURO	¥108 ¥119	¥111 ¥130	¥110 ¥130	¥112 ¥127	¥111 ¥128	¥109 ¥121	¥107 ¥120	¥108 ¥121

Note: From FY2019/3, a part of sales promotion expenses is deducted from revenue, which had been booked as SG&A previously. FY2019/3 Revenue is an amount after deducting ¥8.3B.

Forecast for the year ending March 31, 2020: Financial Highlights by Segments




		FY2017/3	FY2018/3	FY2019/3		FY2020/3 Forecast			
Billions of yen		Full year	Full year	1H	2H	Full year	1H	2H	Full year
Imaging Products Business	Revenue	383.0	360.7	150.9	145.2	296.1	119.0	116.0	235.0
	Operating	17.1	30.2	13.2	8.8	22.0	2.0	-12.0	-10.0
	Profit	(28.1)	(36.0)	(13.6)	(9.0)	(22.6)	(2.2)	(-7.2)	(-5.0)
Precision Equipment Business	Revenue	248.0	226.3	121.6	152.9	274.5	115.1	139.9	255.0
	Operating	13.4	53.3	29.8	51.9	81.7	25.4	25.6	51.0
	Profit	(48.1)	(53.3)	(29.8)	(51.9)	(81.7)	(25.4)	(25.6)	(51.0)
Healthcare Business	Revenue	55.7	56.8	29.4	36.0	65.4	30.0	35.0	65.0
	Operating	-0.6	-3.2	-2.3	0.4	-1.9	-1.2	0.2	-1.0
	Profit	(-0.1)	(-3.2)	(-2.3)	(0.4)	(-1.9)	(-1.2)	(0.2)	(-1.0)
Industrial Metrology and Others	Revenue	62.4	73.2	33.7	38.8	72.5	26.7	38.3	65.0
	Operating	3.7	5.0	2.7	4.2	6.9	2.4	1.6	4.0
	Profit	(5.5)	(7.8)	(3.5)	(4.0)	(7.5)	(2.4)	(1.6)	(4.0)
Corporate P/L non-attributable to any reportable segments	Revenue	_	_	_	_	_	_	_	-
	0 00.009	-32.8	-29.1	-12.8	-13.3	-26.1	-11.1	-12.9	-24.0
	Profit	(-27.5)	(-29.1)	(-12.8)	(-12.8)	(-25.6)	(-9.4)	(-12.9)	(-22.3)
Consolidated	Revenue	749.2	717.0	335.7	372.9	708.6	291.0	329.0	620.0
	Operating	0.7	56.2	30.6	52.0	82.6	17.5	2.5	20.0
	Profit	(54.1)	(64.9)	(31.8)	(52.6)	(84.4)	(19.4)	(7.3)	(26.7)

Note: From FY2019/3, a part of sales promotion expenses is deducted from revenue, which had been booked as SG&A previously. FY2019/3 Revenue is an amount after deducting ¥8.3B. Figures in parentheses are the operating profit excluding the restructuring relevant expenses.

1st half of the year ending March 31, 2020: Financial Position Breakdown





Note: A breakdown of interest-bearing debt as of December 31, 2019 is ¥29.9B in bonds and ¥110.5B in other borrowings.

(Leases Liabilities at the beginning of FY2020/3 has increased approx. ¥17.0B upon the adoption of IFRS 16.)


Equity ratio is ratio of equity attributable to owners of the parent to total assets. Cash and Cash Equivalents excludes time deposits with maturities of thee months or more.


Forecast for the year ending March 31, 2020: Capital Expenditures, Depreciation and Inventory



CAPITAL EXPENDITURES, DEPRECIATION

INVENTORY BREAKDOWN






Note: In FY2020/3, "CAPITAL EXPENDITURES" includes the leased assets of approx. ¥3.0B upon the adoption of IFRS16.

"DEPRECIATION" includes the amortization of capitalized R&D costs from the FY2018/3 and depreciation of the leased asset of approx. ¥4.0B in FY2020/3, as mentioned above.


1st to 3rd quarter of the year ending March 31, 2020: Revenue Breakdown








BY REGION




Forecast for the year ending March 31, 2020: R&D Expenditures



R&D EXPENDITURES




R&D EXPENDITURES BREAKDOWN



Note: R&D expenditures after FY2018/3 includes capitalization of some development expenditure.

Cash Flow History






Note: FCF (free cash flows) = CF from operating activities + CF from investing activities; Japanese Standard is employed for FY2015/3 and prior, and IFRS is adopted for FY2016/3 and after. FCF + CF from financial activities + Effect of exchange rate changes on cash and cash equivalents = net increase (decrease) in cash and cash equivalents

Shareholder Return History and Forecast






Note: Buy-back of shares at approx. ¥10.0B was conducted in Q1 of FY2020/3. Another buy-back of approx. ¥30B is planned in the period between Q3 and Q4 of FY2020/3.

Imaging Products Business: Sales Units






Forecast for the year ending March 31, 2020: Precision Equipment Business Sales Units






SEMICONDUCTOR LITHOGRAPHY SYSTEMS SALES BY TECHNOLOGY (INCL. REFURBISHED)



Note: The unit sales of new semiconductor lithography systems is 17 units in FY2018/3, 21 units in FY2019/3 and 30 units (forecast) in FY2020/3.


Precision Equipment Business: Sales Units





Precision Equipment Business: Sales Units





Forecast for the year ending March 31, 2020: Foreign Exchange Impact



	Exchange Rate	Financial Impact from Fluctuation by 1 yen			
	FY2020/3 Forecast for Q4	Revenue Q4	Operating Profit Q4		
US \$	¥105	Approx. ¥0.6billion	Approx. ¥0.1billion		
EURO	¥120	Approx. ¥0.2billion	Approx. ¥0.1billion		

Note: The foreign exchange impact above is made on the assumption that emerging-market currencies move according to the influence of US\$ and Euro.

Disclaimer Regarding Forecast and Projections



Forward-looking statements for earnings and other performance data contained herein are based on information currently available to the Company, and all potential risks and uncertainties are taken into account. The Company asks that investors understand that changes in conditions may cause actual performance to significantly differ from these projections.

